F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, Medicinal Chemistry, CH-4070 Basel, Switzerland.
Bioorg Med Chem Lett. 2009 Nov 1;19(21):6106-13. doi: 10.1016/j.bmcl.2009.09.024. Epub 2009 Sep 12.
SAR studies of a recently described SST5R selective benzoxazole piperidine lead series are described with particular focus on the substitution pattern on the benzyl and benzoxazole side-chains. Introduction of a second meta substituent at the benzyl unit significantly lowers residual hH1 activity and insertion of substituents onto the benzoxazole periphery entirely removes remaining h5-HT2B activity. Compounds with single digit nM activity, functional antagonism and favorable physicochemical properties endowed with a good pharmacokinetic profile in rats are described which should become valuable tools for exploring the pharmacological role of the SST5 receptor in vivo.
描述了最近描述的 SST5R 选择性苯并恶唑哌啶先导系列的 SAR 研究,特别关注苄基和苯并恶唑侧链上的取代模式。在苄基单元上引入第二个间位取代基会显著降低残留的 hH1 活性,而在苯并恶唑外围插入取代基则完全去除剩余的 h5-HT2B 活性。描述了具有单数字 nM 活性、功能拮抗作用和有利物理化学性质的化合物,在大鼠中具有良好的药代动力学特征,这些化合物应该成为探索 SST5 受体在体内药理学作用的有价值的工具。